Compare Abbott Laboratories (ABT) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Quanta Services Inc — how do they compare? Abbott Laboratories trades at $110.95 (market cap $187.95B), while Quanta Services Inc trades at $686.83 (market cap $100.82B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | PWR | |
|---|---|---|
Market Cap | $187.95B | $100.82B |
Sector | Health | Industrials |
52-Week High | $136.62 | $785.24 |
52-Week Low | $82.57 | $372.50 |
Enterprise Value | $214.96B | $106.91B |
Dividend Yield | 2.32% | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
PWR trades at $680.97, up 3.04% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust revenue growth, reaching $28.48B in 2025, and raised its 2026 outlook, supported by a record backlog and infrastructure demand. However, valuation ratios like a P/E of 76.73 and P/S of 3.1 are elevated, indicating high expectations.
The outlook is positive due to accelerating infrastructure investments and analyst consensus favoring buys, with a price target of $809.75. Risks include high valuation sensitivity, project execution challenges, and macroeconomic pressures on capital spending. Earnings growth remains the key catalyst for further upside, but investors should weigh premium pricing against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
